Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics Inc Cl A (NQ: VERA )

42.72 +2.52 (+6.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vera Therapeutics Inc Cl A

< Previous 1 2 Next >
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Scheduled to Present at November Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Scheduled to Present at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.